Advice on Decision Making for Frontline Treatment of HCC

September 21, 2018
Andrew Zhu, MD, PhD

Andrew Zhu, MD, PhD, director of Liver Cancer Research and Medicine at Massachusetts General Hospital, shares his advice on making decisions for frontline treatment of patients with hepatocellular carcinoma.

Andrew Zhu, MD, PhD, director of Liver Cancer Research and Medicine at Massachusetts General Hospital, shares his advice on making decisions for frontline treatment of patients with hepatocellular carcinoma (HCC).

According to Zhu, most clinicians base these decisions off the best available data. If the overall survival (OS) difference is available, that will guide clinicians in choosing one agent over another.